Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in locally advanced gastric cancer
NCT05101616Phase 2Suspended
- Sponsor
- Shanghai Minimally Invasive Surgery Center
- Start
- Jul 2022
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), sponsored by Shanghai Minimally Invasive Surgery Center. Started Jul 2022; status: suspended.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05101616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101616.